Abstract
Genome-wide association studies (GWAS) have identified genetic loci associated with risk of Alzheimer’s disease (AD), but underlying mechanisms are largely unknown. We conducted a metabolome-wide association study (MWAS) of AD-associated loci from GWAS using untargeted metabolic profiling (metabolomics) by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). We identified an association of lactosylceramides (LacCer) with AD-related single nucleotide polymorphisms (SNPs) in ABCA7 (P = 5.0x 10−5 to 1.3 x 10−44). We show that plasma LacCer concentrations are associated with cognitive performance in humans and concentrations of sphingomyelins, ceramides, and hexose-ceramides were altered in brain tissue from ABCA7 knock out mice, compared to wild type (WT) (P =0.049 to 1.4 x10−5). We then used Mendelian randomisation to show that the association of LacCer with AD risk is potentially causal. Our work suggests that risk for AD arising from functional variations in ABCA7 are mediated at least in part through ceramides. Modulation of their metabolism or downstream signalling may offer new therapeutic opportunities for AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the UK Dementia Research Institute at Imperial College, which receives its funding from UK DRI Ltd. funded by the UK Medical Research Council, Alzheimers Society and Alzheimers Research UK. AD is funded by a Wellcome Trust seed award (206046/Z/17/Z). RM is funded by the Presidents PhD Scholarship from Imperial College London. PMM acknowledges generous personal and research support from the Edmond J Safra Foundation and Lily Safra and a National Institute for Health Research (NIHR) Senior Investigator Award (to 2020). JLG is funded by the UK Medical Research Council (MRC) (MC_UP_A090_1006, MC_PC_13030, MR/P011705/1, MR/P01836X/1 and MAP UK) and Wellcome Trust (MetaboFlow). MK is funded by the NIHR Imperial Biomedical Research Centre (BRC), Wallenberg Clinical Scholars, Academy of Finland and Swedish Research Council. AS is funded by the Academy of Finland (287490, 294061, 319318), European Research Council (804371), Alzheimerfonden and Region Stockholm ALF (Sweden). This work was supported by the MRC and NIHR [grant number MC_PC_12025]. PE is the director of the MRC Centre for Environment and Health (MR/L01341X/1). He also acknowledges support from the NIHR Health Protection Research Units in Chemical and Radiation Threats and Hazards and in Health Impact of Environmental Hazards. PE is a co-director of the Health Data Research UK London site, which is supported, among others, by MRC, NIHR, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Wellcome Trust, and British Heart Foundation (BHF). PE acknowledges support from the BHF Centre for Research Excellence at Imperial College. Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre (BRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. Since 1999, the Rotterdam Study is approved by a special permit issued by the Ministry of Health, Welfare, and Sport of The Netherlands (under Article 3 of the Population Screening Act (the WBO, in Dutch)). As such, the Rotterdam Study is exempted from obtaining separate IRB approvals for the sub-studies that are conducted within the framework of the Rotterdam Study. 2. The Airwave study has ethical approval from the National Health Service Multi-site Research Ethics Committee (MREC/13/NW/0588). Each participant provided informed written consent to participate in the study following procedures approved by the MREC. 3. The FINGER has been approved by the coordinating ethics committee of the hospital district for the Helsinki and Uusimaa region. Participants give their written informed consent before enrollment in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests PMM has received consultancy fees from Biogen, Roche, Celgene and Ipsen Pharmaceuticals. He has received honoraria or speakers’ fees from Novartis, Biogen, Neurodiem and Medscape and has received research or educational funds from Biogen, Novartis and GlaxoSmithKline.
Data Availability
The data is available per request. For cohort data, agreement of the cohort management team is needed.
